
Keywords: Cancer; Target therapy; Prodrug; MDR; Multidrug resistance; ROS; Reactive oxygen species; GSH; Glutathione; ADCs; Antibody-drug conjugates; ADEPT; Antibody-directed enzyme prodrug therapy; GDEPT; Gene-directed enzyme prodrug therapy; HIF; Hypoxia-inducibl